China Pharma regains NYSE American compliance after reverse stock split

CHINA PHARMA HOLDINGS, INC.

Received NYSE American notice on March 27, 2024 confirming compliance with continued listing standards.
Resolved low selling price deficiency (Section 1003(f)(v)) via 1-for-5 reverse stock split on March 6, 2024.
".BC" indicator to be removed; company removed from noncompliant issuers list.
NYSE American cautioned that no cure period exists if stock again trades at abnormally low levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.